Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants

Immune checkpoint inhibitors (ICIs) are yet to have a major advantage over conventional therapies, as only a fraction of patients benefit from the currently approved ICIs and their response rates remain low. We investigated the effects of different ICIs—anti-programmed cell death protein 1 (PD-1), a...

Descripción completa

Detalles Bibliográficos
Autores principales: Saleh, Reem, Toor, Salman M., Al-Ali, Dana, Sasidharan Nair, Varun, Elkord, Eyad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349021/
https://www.ncbi.nlm.nih.gov/pubmed/32616706
http://dx.doi.org/10.3390/genes11060703

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349021/
https://www.ncbi.nlm.nih.gov/pubmed/32616706
http://dx.doi.org/10.3390/genes11060703

Ejemplares similares